<DOC>
	<DOC>NCT00144911</DOC>
	<brief_summary>This study evaluates the effect of two medicines on COPD (Chronic Obstructive Pulmonary Disease) exacerbations. This study will last up to 56 weeks, and subjects will visit the clinic 10 times. Subjects will be given breathing tests and will record their breathing symptoms daily on diary cards. All study related medicines and medical examinations will be provided at no cost. The two drugs used in this study have been approved by the FDA for use in patients with COPD.</brief_summary>
	<brief_title>ADVAIR® DISKUS® Inhaler (Fluticasone Propionate/Salmeterol) Versus SEREVENT® DISKUS® Inhaler (Salmeterol) For The Treatment Of Chronic Obstructive Pulmonary Disease Exacerbations. ADVAIR® DISKUS® Inhaler and SEREVENT® DISKUS® Inhaler Are Trademarks of the GSK Group of Companies.</brief_title>
	<detailed_description>A Randomized, Double-Blind, Parallel Group, 52-week Study to Compare the Effect of the Fluticasone Propionate/Salmeterol DISKUS® inhaler Combination Product 250/50mcg twice daily (BID) with Salmeterol DISKUS® inhaler 50mcg BID on the Annual Rate of Moderate/Severe Exacerbations in Subjects with Chronic Obstructive Pulmonary Disease (COPD)</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Fluticasone Propionate, Salmeterol Xinafoate Drug Combination</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>Diagnosis of COPD (chronic obstructive pulmonary disease). Current or previous cigarette smokers with a smoking history of at least 10 packyears. History of a least 1 COPD exacerbation in the 12 months prior to screening. Forced expiratory volume in one second (FEV1) of less than or equal to 50% of predicted normal. Current diagnosis of asthma. Additional respiratory disorders other than COPD (eg, sarcoidosis, alpha1 antitrypsin deficiency, cystic fibrosis, or active tuberculosis). Concurrent use of longacting betaagonists, longacting anticholinergics, inhaled and oral corticosteroids, theophylline, investigational medications, ritonavir, and antileukotrienes. Lung resection surgery within 1 year of screening. Abnormal and clinically significant ECG findings at screening. Other inclusion and exclusion criteria will be evaluated at the first study visit.</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>exacerbations</keyword>
	<keyword>breathing</keyword>
	<keyword>chronic obstructive pulmonary disease</keyword>
</DOC>